Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.39 USD | +5.69% | +0.19% | +25.93% |
04-24 | Transcript : Lantern Pharma Inc. - Special Call | |
04-22 | Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 57.99M 4.63B |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.84B | Net income 2025 * | -28M -2.24B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.65
x | P/E ratio 2025 * |
-2.86
x | Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.94% |
Latest transcript on Lantern Pharma Inc.
1 day | +5.69% | ||
1 week | +0.19% | ||
Current month | +5.69% | ||
1 month | -43.32% | ||
3 months | +27.42% | ||
6 months | +110.55% | ||
Current year | +25.93% |
Managers | Title | Age | Since |
---|---|---|---|
Panna Sharma
CEO | Chief Executive Officer | 53 | 30/06/18 |
David Margrave
DFI | Director of Finance/CFO | 64 | 31/05/18 |
Reggie Ewesuedo
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Panna Sharma
CEO | Chief Executive Officer | 53 | 30/06/18 |
Director/Board Member | 73 | 07/06/22 | |
Donald Keyser
CHM | Chairman | 71 | 31/12/17 |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 5.39 | +5.69% | 123,183 |
30/04/24 | 5.1 | +3.45% | 84,244 |
29/04/24 | 4.93 | -10.36% | 302,806 |
26/04/24 | 5.5 | +0.73% | 128,985 |
25/04/24 | 5.46 | +1.49% | 124,629 |
Delayed Quote Nasdaq, May 01, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.93% | 54.87M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- LTRN Stock